医学
精密医学
精确肿瘤学
液体活检
靶向治疗
临床肿瘤学
肺癌
药物开发
肿瘤科
癌症
生物信息学
内科学
药品
病理
药理学
生物
作者
Aakash Desai,Neha K. Reddy,Vivek Subbiah
出处
期刊:Cancer
[Wiley]
日期:2023-03-22
卷期号:129 (11): 1634-1642
被引量:1
摘要
The advent of precision medicine has changed the landscape of oncologic biomarkers, drug discovery, drug development, and, more importantly, outcomes for patients with cancer. Precision oncology entails the genomic profiling of tumors to detect actionable aberrations. The advances in clinical next-generation sequencing from both tumor tissue and liquid biopsy and availability of targeted therapies has rapidly entered mainstream clinical practice. In this review, recent major developments in precision oncology that have affected outcomes for patients with cancer are discussed. Rapid clinical development was seen of targeted agents across various mutational profiles such as KRASG12C (which was considered "undruggable" for almost 4 decades), Exon 20 insertions, and RET mutations. Approaches to precision chemotherapy delivery by the introduction of antibody drug conjugates in the armamentarium against lung cancer has been appreciated.
科研通智能强力驱动
Strongly Powered by AbleSci AI